Frontiers in Nutrition,
Год журнала:
2023,
Номер
10
Опубликована: Фев. 16, 2023
Non-alcoholic
fatty
liver
disease
(NAFLD)
is
frequently
associated
with
metabolic
disorders,
being
highly
prevalent
in
obese
and
diabetic
patients.
Many
concomitant
factors
that
promote
systemic
inflammation
are
involved
NAFLD
pathogenesis,
a
growing
body
of
evidence
highlighting
the
key
role
gut
microbiota.
Indeed,
gut-liver
axis
has
strong
impact
promotion
progression
wide
spectrum
its
manifestations,
claiming
efforts
to
find
effective
strategies
for
microbiota
modulation.
Diet
among
most
powerful
tools;
Western
diet
negatively
affects
intestinal
permeability
composition
function,
selecting
pathobionts,
whereas
Mediterranean
fosters
health-promoting
bacteria,
favorable
on
lipid
glucose
metabolism
inflammation.
Antibiotics
probiotics
have
been
used
improve
features,
mixed
results.
More
interestingly,
medications
treat
NAFLD-associated
comorbidities
may
also
modulate
Drugs
treatment
type
2
diabetes
mellitus
(T2DM),
such
as
metformin,
glucagon-like
peptide-1
(GLP-1)
agonists,
sodium-glucose
cotransporter
(SGLT)
inhibitors,
not
only
regulation
homeostasis,
but
reduction
fat
content
inflammation,
they
shift
towards
healthy
phenotype.
Even
bariatric
surgery
significantly
changes
microbiota,
mostly
due
modification
gastrointestinal
anatomy,
parallel
improvement
histological
features
NAFLD.
Other
options
promising
effects
reprogramming
axis,
fecal
microbial
transplantation
(FMT)
next-generation
deserve
further
investigation
future
inclusion
therapeutic
armamentarium
Nutrients,
Год журнала:
2019,
Номер
11(3), С. 677 - 677
Опубликована: Март 21, 2019
Non-alcoholic
fatty
liver
disease
(NAFLD)
is
a
major
global
health
threat
due
to
its
growing
incidence
and
prevalence.
It
becoming
the
leading
cause
of
in
addition
strong
association
with
cardio-metabolic
disease.
Therefore,
prevention
treatment
are
public
interest.
Therapeutic
approaches
emphasize
lifestyle
modifications
including
physical
activity
adoption
healthy
eating
habits
that
intend
mainly
control
body
weight
risk
factors
associated
metabolic
syndrome.
Lifestyle
interventions
may
be
reinforced
by
pharmacological
advanced
stages,
though
there
still
no
registered
drug
for
specific
NAFLD.
The
purpose
this
review
assess
evidence
available
regarding
impact
dietary
recommendations
against
NAFLD,
highlighting
effect
macronutrient
diet
composition
patterns
management
International Journal of Environmental Research and Public Health,
Год журнала:
2019,
Номер
16(17), С. 3104 - 3104
Опубликована: Авг. 26, 2019
New
evidence
suggests
that
non-alcoholic
fatty
liver
disease
(NAFLD)
has
a
strong
multifaceted
relationship
with
diabetes
and
metabolic
syndrome,
is
associated
increased
risk
of
cardiovascular
events,
regardless
traditional
factors,
such
as
hypertension,
diabetes,
dyslipidemia,
obesity.
Given
the
pandemic-level
rise
NAFLD—in
parallel
increasing
prevalence
obesity
other
components
syndrome—and
its
association
poor
outcomes,
question
how
to
manage
NAFLD
properly,
in
order
reduce
burden
incident
both
timely
highly
relevant.
This
review
aims
summarize
current
knowledge
between
disease,
also
discuss
possible
clinical
strategies
for
assessment,
well
spectrum
available
therapeutic
prevention
treatment
downstream
events.
International Journal of Molecular Sciences,
Год журнала:
2021,
Номер
22(5), С. 2350 - 2350
Опубликована: Фев. 26, 2021
Non-alcoholic
fatty
liver
disease
(NAFLD)
is
to
date
the
most
common
chronic
in
clinical
practice
and,
consequently,
a
major
health
problem
worldwide.
It
affects
approximately
30%
of
adults
general
population
and
up
70%
patients
with
type
2
diabetes
(T2DM).
Despite
current
knowledge
epidemiology,
pathogenesis,
natural
history
NAFLD,
no
specific
pharmacological
therapies
are
until
now
approved
for
this
strategies
have
been
proposed
manage
it.
They
include:
(a)
lifestyle
change
order
promote
weight
loss
by
diet
physical
activity,
(b)
control
main
cardiometabolic
risk
factors,
(c)
correction
all
modifiable
factors
leading
development
progression
advanced
forms
(d)
prevention
hepatic
extra-hepatic
complications.
In
last
decade,
several
potential
agents
widely
investigated
treatment
NAFLD
its
forms—shedding
some
light
but
casting
few
shadows.
include
glucose-lowering
drugs
(such
as
pioglitazone,
glucagon-like
peptide-1
(GLP-1)
receptor
agonists,
sodium-glucose
co-transporter-2
(SGLT-2)
inhibitors),
antioxidants
vitamin
E),
statins
or
other
lipid
lowering
agents,
bile
non-bile
acid
farnesoid
X
activated
(FXR)
others.
This
narrative
review
discusses
detail
different
available
approaches
prevent
treat
forms.
Frontiers in Endocrinology,
Год журнала:
2023,
Номер
13
Опубликована: Янв. 16, 2023
Non-alcoholic
fatty
liver
disease
(NAFLD)
is
a
series
of
diseases,
involving
excessive
lipid
deposition
in
the
and
often
accompanied
by
obesity,
diabetes,
dyslipidemia,
abnormal
blood
pressure,
other
metabolic
disorders.
In
order
to
more
accurately
reflect
its
pathogenesis,
an
international
consensus
renamed
NAFLD
2020
as
(dysfunction)
associated
with
(MAFLD).
The
changes
diet
lifestyle
are
recognized
non-drug
treatment
strategies;
however,
due
complex
pathogenesis
NAFLD,
current
drug
therapies
mainly
focused
on
pathogenic
factors,
key
links
related
disorders
targets.
There
still
lack
specific
drugs.
clinical
studies,
common
treatments
include
regulation
glucose
metabolism
protect
anti-inflammation.
based
enterohepatic
axis,
targeting
gut
microbiota,
gradually
emerging,
various
new
metabolism-regulating
drugs
also
under
development.
Therefore,
this
review
article
has
comprehensively
discussed
research
advancements
recent
years.
BMJ,
Год журнала:
2021,
Номер
unknown, С. m4747 - m4747
Опубликована: Янв. 18, 2021
ABSTRACT
Non-alcoholic
fatty
liver
disease
is
a
very
common
medical
condition,
driven
by
combination
of
genetic
and
lifestyle
factors,
ultimately
producing
severe
chronic
increased
cardiovascular
risk.
Most
people
are
asymptomatic
for
long
time,
their
daily
life
unaffected,
leading
to
difficulty
in
identifying
managing
who
slowly
progress
non-alcoholic
steatohepatitis
(NASH),
NASH-cirrhosis,
eventually
hepatocellular
carcinoma.
Despite
advances
the
understanding
pathogenic
mechanisms
identification
fibrosis
as
strongest
factor
predicting
progression,
no
specific
treatments
have
been
approved
regulatory
agencies.
Outside
controlled
trials,
treatment
generally
limited
intervention
aimed
at
weight
loss.
Pioglitazone
remains
drug
choice
reduce
progression
with
diabetes,
although
it
often
used
off-label
absence
diabetes.
Vitamin
E
mainly
children
may
be
considered
adults
without
Several
drugs
under
investigation
according
agreed
targets
reduced
NASH
activity
worsening
or
improving
NASH.
Anti-inflammatory,
anti-fibrotic
agents
metabolism
modulators
tested
either
phase
III
IIb
randomized
trials;
few
failed,
others
produced
marginally
positive
results,
but
only
being
extension
studies.
The
development
non-invasive,
easily
repeatable
surrogate
biomarkers
and/or
imaging
tools
crucial
facilitate
clinical
studies
limit
biopsy.
Clinical and Molecular Hepatology,
Год журнала:
2022,
Номер
29(1), С. 77 - 98
Опубликована: Окт. 13, 2022
The
initial
presentation
of
non-alcoholic
steatohepatitis
(NASH)
is
hepatic
steatosis.
dysfunction
lipid
metabolism
within
hepatocytes
caused
by
genetic
factors,
diet,
and
insulin
resistance
causes
accumulation.
Lipotoxicity,
oxidative
stress,
mitochondrial
dysfunction,
endoplasmic
reticulum
stress
would
further
contribute
to
hepatocyte
injury
death,
leading
inflammation
immune
in
the
liver.
During
healing
process,
accumulation
an
excessive
amount
fibrosis
might
occur
while
healing.
development
NASH
liver
fibrosis,
gut-liver
axis,
adipose-liver
renin-angiotensin
system
(RAS)
may
be
dysregulated
impaired.
Translocation
bacteria
or
its
end-products
entering
could
activate
hepatocytes,
Kupffer
cells,
stellate
exacerbating
steatosis,
inflammation,
fibrosis.
Bile
acids
regulate
glucose
through
Farnesoid
X
receptors
intestine.
Increased
adipose
tissue-derived
non-esterified
fatty
aggravate
leptin
also
plays
a
role
fibrogenesis,
decreased
adiponectin
resistance.
Moreover,
dysregulation
peroxisome
proliferator-activated
liver,
adipose,
muscle
tissues
impair
metabolism.
In
addition,
RAS
acid
metabolism,
treatment
includes
lifestyle
modification,
pharmacological
therapy,
non-pharmacological
therapy.
Currently,
weight
reduction
modification
surgery
most
effective
However,
vitamin
E,
pioglitazone,
obeticholic
have
been
suggested.
this
review,
we
will
introduce
some
new
clinical
trials
experimental
therapies
for
related
